News Brief

Government Readies Two More Labs For Covid Vaccine Testing From PM CARES Fund

Swarajya Staff

Jul 05, 2021, 02:39 PM | Updated 02:39 PM IST

DBT-NIAB Central Drugs Laboratory for COVID-19 Vaccine Testing (Image Credits: PIB)
DBT-NIAB Central Drugs Laboratory for COVID-19 Vaccine Testing (Image Credits: PIB)

In a significant step, two more Central Drug Laboratories have been readied at Pune and Hyderabad for Covid vaccine testing. The step has been taken in the wake of the Covid-19 pandemic, and considering the enhanced production of Covid vaccines in the country.

Currently, India has a Central Drugs Laboratory (CDL) at Kasauli, which is the National Control Laboratory for testing and pre-release certification of immunobiologicals (vaccines and antisera) meant for human use in India.

According to a Science & Technology Ministry statement, the facility at the National Centre for Cell Science, Pune, has now been notified as a Central Drugs Laboratory for testing and lot release of Covid-19 vaccines, through a gazette notification issued by the Health & Family Welfare Ministry on June 28.

The facility at the National Institute of Animal Biotechnology, Hyderabad is likely to receive necessary notification shortly, it said.

"With generous support from PM CARES Fund trust in a very short span of time, both the institutions, through relentless efforts, have set up the state-of-the-art modern facilities for this purpose.

"The facilities are expected to test approx 60 batches of vaccines per month. The facilities are geared up to test existing Covid-19 vaccines and other newer Covid-19 vaccines as per demand of the nation. This will not only expedite the vaccine manufacture and supply but also be logistically convenient considering that both Pune and Hyderabad are the two vaccine manufacturing hubs," the statement said.

The Department of Biotechnology, under the Science & Technology Ministry, now has set up facilities in its autonomous research institutes, the NCCS, and the NIAB, for batch testing and quality control of vaccines.

Since the COVID-19 pandemic, Department of Biotechnology has been in the forefront contributing to various COVID-19 related activities including Vaccine Development, Diagnostics and testing, bio-banking and genomic surveillance, in addition to fundamental research and also building a strong ecosystem for translational research

DBT-NCCS and DBT-NIAB have been the pillars for many aspects of infectious disease related work in India and have contributed to advancement of cutting-edge research output in frontier areas of Biotechnology relevant to human health and disease.

With IANS Inputs

Get Swarajya in your inbox.